PMJ Launches New TEREA Hybrid Pod Line in Japan

Aug.06.2024
PMJ Launches New TEREA Hybrid Pod Line in Japan
PMJ Japan introduces new TEREA Hybrid Pearl Green Fruit and Smooth Mint pods for IQOS ILUMA on August 6.

According to PR Times' report on August 6th, Philip Morris Japan Company (PMJ) has launched two new products under its IQOS ILUMA brand, the "TEREA Hybrid Pearl Green Fruit" and the "TEREA Hybrid Pearl Smooth Mint" pods.

PMJ Launches New TEREA Hybrid Pod Line in Japan
New product information from Terea. Image source: PMJ


The new product will be launched nationwide on IQOS online store and in seven IQOS stores on August 28, and will be available for sale in select electronics stores, convenience stores, and national tobacco retailers starting on September 2.


The company stated that with the release of this new product, the TEREA brand's product line has expanded to 22 varieties.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

BAT Executive: Company’s Smokeless Products Outperform Cigarettes in Japan and UK, Over 70% Share in Sweden
BAT Executive: Company’s Smokeless Products Outperform Cigarettes in Japan and UK, Over 70% Share in Sweden
James Murphy, Director of Research at British American Tobacco (BAT), said in a podcast that the company is accelerating its transition to smoke-free products, with sales in Japan and the UK already surpassing cigarettes, and a share of over 70% in Sweden.
Sep.01 by 2FIRSTS.ai
Malaysia Seizes 300,000 Smuggled Vapes and Components, Suspected for Singapore Market, Labeled with “Salthub”
Malaysia Seizes 300,000 Smuggled Vapes and Components, Suspected for Singapore Market, Labeled with “Salthub”
Malaysian Customs in Port Klang seized about 300,000 smuggled e-cigarettes and components. The shipment, disguised as furniture and labeled "Salthub," lacked required health warnings. It was likely smuggled to Singapore by road. The UNODC has warned that Malaysia is a key transit point for drug and e-cigarette smuggling to Southeast Asia.
Sep.03 by 2FIRSTS.ai
InterTabac 2025 Photo Gallery|HQD, SKE, and REJO Secure Prime Outdoor Ads; Nicotine Pouch Brands Lead the Marketing Blitz
InterTabac 2025 Photo Gallery|HQD, SKE, and REJO Secure Prime Outdoor Ads; Nicotine Pouch Brands Lead the Marketing Blitz
nterTabac 2025 is officially underway. 2Firsts is on the ground, capturing the core brand advertising displays and bringing an exclusive photo gallery to cover the exhibition's dynamic trends, industry insights, and brand highlights.
Sep.18
Smuggled cigarettes and e-cigarettes seized in Türkiye's Manisa province, suspect detained
Smuggled cigarettes and e-cigarettes seized in Türkiye's Manisa province, suspect detained
On September 4th, a team from the Manisa Provincial Gendarmerie Command seized a large quantity of smuggled cigarettes and e-cigarettes during an operation and detained a suspect. A search of the suspect's vehicle revealed 137 e-cigarettes, 530 packs of smuggled cigarettes, and 41 boxes of nicotine gum. The vehicle was towed to a trustee's parking lot, and the suspect has been charged with violating Law No. 5607 on Combating Smuggling.
Sep.08
InterTabac 2025 Highlights Europe’s Vaping Dilemma: Tighter Regulation, Constrained Innovation
InterTabac 2025 Highlights Europe’s Vaping Dilemma: Tighter Regulation, Constrained Innovation
According to 2Firsts’ on-site observations, the vaping halls at InterTabac 2025 have visibly cooled: fewer exhibitors, a weaker presence from major brands, and scarce stage activations; new product momentum is weak and homogenization has intensified. Tightening regulation and policy uncertainty are squeezing innovation, pushing companies to replicate proven models—overall, a “cautious showcase.”
Sep.19 by 2FIRSTS.ai
U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months
U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months
The U.S. Food and Drug Administration (FDA) has added Cytisinicline, a plant-based therapy developed by Achieve Life Sciences for nicotine vaping addiction, to its new National Priority Voucher (CNPV) program. The initiative shortens drug review timelines from 10–12 months to just 1–2 months, expediting approval for treatments that address major public health needs.
Oct.20 by 2FIRSTS.ai